TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use
Clinical trials involved more than 10,000 patients in 15 countries.

The Therapeutic Goods Administration (TGA) has cleared a groundbreaking Ozempic-style pill for Australians to aid with weight loss and treat type 2 diabetes.
The daily GLP-1 pill called Foundayo is expected to be available in just days after the TGA’s ruling on Tuesday.
Foundayo is a small-molecule GLP-1 which targets and simulates a natural hormone in the body to control hunger and slow digestion, the same as popular drugs such as Ozempic and Wegovy.
Sign up to The Nightly's newsletters.
Get the first look at the digital newspaper, curated daily stories and breaking headlines delivered to your inbox.
By continuing you agree to our Terms and Privacy Policy.The Australian arm of US pharmaceutical company Lilly said the drug is a first-of-its-kind GLP-1 pill, which can be taken at any time of the day, without food or water restrictions.
National Association of Clinical Obesity Services President and Associate Professor Samantha Hocking said the clearance could help stem obesity in Australia.
“Australia is grappling with rising rates of overweight and obesity, which now affect around 13 million adults,” Hocking said.
“Obesity is a complex chronic disease that increases the risk of at least 30 other serious medical conditions, ranging from cancer and cardiovascular disease to type 2 diabetes..
“The impact of obesity and type 2 diabetes on individuals, families and our health system highlights the urgent need for stronger prevention efforts and improved access to clinically proven treatment options.”

The Australian arm of US pharmaceutical company Lilly also celebrated the achievement as the result of more than a decade of research.
“Foundayo clinical trials involved more than 10,000 patients in 15 countries, including partnerships with a dozen Australian hospitals and clinics,” Lilly Australia General Manager Dr Manny Simons said.
“Now that Foundayo can be prescribed, our focus is on ways to deliver broader access for Australians who may benefit from this new medicine.”
The drug is now available through private presciption, but is yet to be added to the Pharmaceutical Benefits Scheme.
Lilly Australia has warned the use of Foundayo with other GLP-1s is “not recommended” and those who take the drug may experience side effects.

“The most common side effects affect the digestive system. In clinical trials these effects were mostly mild or moderate in severity and were more frequent during dose escalation, decreasing over time,” the company warns.
“Warnings include low blood sugar when used with insulin or a sulfonylurea and pancreatitis.
“Foundayo should not be used in pregnancy or by people hypersensitive to orforglipron or any ingredient, and some medicines interact with it.”
It’s the latest GLP-1 pill to be approved by the TGA, following Wegovy just weeks prior.
Originally published on 7NEWS
